Meyer J S
Breast Cancer Res Treat. 1986;7(3):171-80. doi: 10.1007/BF01806247.
A thymidine labeling study of cell kinetics of 61 in situ breast carcinomas showed relationships between histological characteristics and kinetics. The thymidine labeling index (TLI) was significantly lower in cribriform-papillary intraductal carcinoma (median 1.30%, geometric mean 1.18%, mean 1.83 +/- 0.45%) and lobular carcinoma in situ (median 1.43%, geometric mean 1.12%, mean 1.63 +/- 0.46%) than in comedo intraductal carcinoma (median 4.40%, geometric mean 3.74%, mean 5.15 +/- 0.86%). The results for solid intraductal carcinoma, which is a less well defined and more heterogeneous entity, were intermediate (median 2.45%, geometric mean 2.40%, mean 3.32 +/- 0.80%). When invasive carcinoma was also available for kinetic study, the TLI of in situ and invasive components were usually similar (r = 0.66). The data indicate that the TLI usually does not change during the transition from in situ to invasive carcinoma. Cribriform-papillary intraductal carcinoma is a slowly proliferating entity that gives rise to slowly proliferating invasive carcinomas with relatively high levels of estrogen and progesterone receptors. Lobular carcinoma in situ similarly has low proliferative rates and gives rise to slowly proliferating invasive carcinomas. Intraductal comedocarcinoma has relatively high proliferative rates and gives rise to invasive carcinomas with high proliferative rates that often are receptor-negative. Nine of the 11 in situ carcinomas that were associated with invasive tumor and subsequent local recurrence or metastasis had TLIs above the median, and seven were comedo type with high TLIs. Our observations from thymidine labeling are consistent with a viewpoint regarding cribriform-papillary intraductal carcinoma as relatively bland, and comedo intraductal carcinoma as a distinctly more dangerous entity. Solid intraductal carcinoma seems to resemble cribriform-papillary more closely than comedo intraductal carcinoma.
一项对61例乳腺原位癌进行的细胞动力学的胸腺嘧啶核苷标记研究显示了组织学特征与动力学之间的关系。筛状-乳头状导管内癌（中位数1.30%，几何均数1.18%，均值1.83±0.45%）和小叶原位癌（中位数1.43%，几何均数1.12%，均值1.63±0.46%）的胸腺嘧啶核苷标记指数（TLI）显著低于粉刺性导管内癌（中位数4.40%，几何均数3.74%，均值5.15±0.86%）。实性导管内癌是一种定义不太明确且异质性更强的实体，其结果处于中间水平（中位数2.45%，几何均数2.40%，均值3.32±0.80%）。当浸润性癌也可用于动力学研究时，原位和浸润成分的TLI通常相似（r = 0.66）。数据表明，从原位癌转变为浸润性癌的过程中，TLI通常不会改变。筛状-乳头状导管内癌是一种增殖缓慢的实体，会发展为雌激素和孕激素受体水平相对较高的增殖缓慢的浸润性癌。小叶原位癌同样增殖率较低，并发展为增殖缓慢的浸润性癌。导管内粉刺癌具有相对较高的增殖率，并发展为增殖率高且通常为受体阴性的浸润性癌。11例与浸润性肿瘤及随后局部复发或转移相关的原位癌中有9例的TLI高于中位数，其中7例为粉刺型且TLI较高。我们从胸腺嘧啶核苷标记得出的观察结果与以下观点一致，即筛状-乳头状导管内癌相对温和，而粉刺性导管内癌是明显更危险的实体。实性导管内癌似乎比粉刺性导管内癌更接近筛状-乳头状癌。
